The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...
Guest blog by Ronald Eberhard
The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...
The € 7.4 billion for Covid-19 product and vaccine development needs a few strings...
On 4 May 2020, European Commission President Ursula von der Leyen hosted the Coronavirus Global Response conference, an on-line pledging event to accelerate the...
Will the European Court of Justice put a stop to the evergreening of Truvada...
Truvada, the fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a critical medicine in both HIV treatment and prevention. It is...
WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending...
On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...
Commission report on competition enforcement in the pharmaceutical sector
Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...
Transfer of technology and know-how for the production of pandemic-related health products in the...
A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot
During...
UN “Pact for the Future” intellectual property actions need revision to ensure innovation and...
UPDATE: From 22-23 September 2024, the Summit of the Future took place and adopted the Pact for the Future. The intellectual property paragraph of...
Wrapping up 2023 with some noteworthy medicines, law and policy developments
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...
Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...
Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...